First AD

Second AD

Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2 

Briefly discuss your general treatment approach in patients with EGFR-mutant NSCLC.

What treatment options are available? What is the standard of care in this setting?

What factors do you consider in guiding treatment selection?

Please review key efficacy and safety data from FLAURA2 evaluating 1L osimertinib with chemotherapy in patients with EGFR-mutant advanced NSCLC.(

Janne, et al. WCLC 2023. Abstract PL03.13

Planchard, et al. ESMO 2023. Abstract LBA68

What implications may these findings have on clinical practice?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates  

Peer Exchange

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC. 